According to the Xinhua Pharmaceutical announcement, the company has received the “Drug Registration Certificate” for dapoxetine hydrochloride tablets approved and issued by the State Drug Administration. The drug is a prescription drug with 4 types of chemicals, 30 mg, and is suitable for treating male premature ejaculation patients aged 18 to 64. In April 2025, the company submitted the registration application for the domestic production and marketing license of the drug and was accepted, and the registration was approved in August 2026. This certification will further enrich the company's formulation product line and enhance market competitiveness. There is uncertainty in the drug sales business. Investors are kindly requested to pay attention to investment risks.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.